Apr 24, 2026
Summary Generalized Myasthenia Gravis (gMG) is a chronic autoimmune neuromuscular disorder, with ~195,000 diagnosed patients across seven major markets in 2025, projected to reach ~250,000 by 2036. Despite recent approvals of FcRn blockers and complement inhibitors, major unmet needs remain, including unpred...
Read More...
Aug 01, 2022
Though a rare disease, generalized myasthenia gravis (gMG) still affects around 60,000 people in the US and another 100,000 in EU-5 and Japan. As per our analysis, the total diagnosed prevalent cases of gMG were approx 116K in the 7MM in 2021. These numbers are further estimated to increase by 2032. Moreover, t...
Read More...
Intratumoral Cancer Therapy: A Potential Weapon To Fight the Battle Against Cancer
Aug 05, 2026
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Newsletter/Whitepaper